237 related articles for article (PubMed ID: 28716898)
1. TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer.
Cooper JM; Ou YH; McMillan EA; Vaden RM; Zaman A; Bodemann BO; Makkar G; Posner BA; White MA
Cancer Res; 2017 Sep; 77(18):5077-5094. PubMed ID: 28716898
[TBL] [Abstract][Full Text] [Related]
2. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
[TBL] [Abstract][Full Text] [Related]
3. Luteoloside induces G
Zhou M; Shen S; Zhao X; Gong X
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):263-269. PubMed ID: 29024631
[TBL] [Abstract][Full Text] [Related]
4. Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
Zhang S; Ma Y; Hu X; Zheng Y; Chen X
J Cell Mol Med; 2019 Feb; 23(2):1333-1342. PubMed ID: 30461193
[TBL] [Abstract][Full Text] [Related]
5. PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation.
Salama MF; Liu M; Clarke CJ; Espaillat MP; Haley JD; Jin T; Wang D; Obeid LM; Hannun YA
Oncogene; 2019 Nov; 38(48):7311-7328. PubMed ID: 31420605
[TBL] [Abstract][Full Text] [Related]
6. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
7. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
[TBL] [Abstract][Full Text] [Related]
8. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Feng FF; Cheng P; Sun C; Wang H; Wang W
Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
[TBL] [Abstract][Full Text] [Related]
10. FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway.
Meng W; Meng J; Jiang H; Feng X; Wei D; Ding Q
Anal Cell Pathol (Amst); 2020; 2020():6021602. PubMed ID: 33354489
[TBL] [Abstract][Full Text] [Related]
11. IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation.
Xie X; Zhang D; Zhao B; Lu MK; You M; Condorelli G; Wang CY; Guan KL
Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6474-9. PubMed ID: 21464307
[TBL] [Abstract][Full Text] [Related]
12. Silencing the FOLR2 Gene Inhibits Cell Proliferation and Increases Apoptosis in the NCI-H1650 Non-Small Cell Lung Cancer Cell Line via Inhibition of AKT/Mammalian Target of Rapamycin (mTOR)/Ribosomal Protein S6 Kinase 1 (S6K1) Signaling.
Xu X; Jiang J; Yao L; Ji B
Med Sci Monit; 2018 Nov; 24():8064-8073. PubMed ID: 30415267
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of interleukin (IL)-24 is required for mediating its anti-cancer activity.
Panneerselvam J; Shanker M; Jin J; Branch CD; Muralidharan R; Zhao YD; Chada S; Munshi A; Ramesh R
Oncotarget; 2015 Jun; 6(18):16271-86. PubMed ID: 26009991
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.
Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
Respir Res; 2014 Feb; 15(1):26. PubMed ID: 24571487
[TBL] [Abstract][Full Text] [Related]
15. PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase.
Ling YH; Aracil M; Zou Y; Yuan Z; Lu B; Jimeno J; Cuervo AM; Perez-Soler R
Clin Cancer Res; 2011 Aug; 17(16):5353-66. PubMed ID: 21690574
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin transporter, SLCO2A1, mediates the invasion and apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway.
Zhu Q; Liang X; Dai J; Guan X
Int J Clin Exp Pathol; 2015; 8(8):9175-81. PubMed ID: 26464663
[TBL] [Abstract][Full Text] [Related]
17. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
18. The IKK-related kinase TBK1 activates mTORC1 directly in response to growth factors and innate immune agonists.
Bodur C; Kazyken D; Huang K; Ekim Ustunel B; Siroky KA; Tooley AS; Gonzalez IE; Foley DH; Acosta-Jaquez HA; Barnes TM; Steinl GK; Cho KW; Lumeng CN; Riddle SM; Myers MG; Fingar DC
EMBO J; 2018 Jan; 37(1):19-38. PubMed ID: 29150432
[TBL] [Abstract][Full Text] [Related]
19. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation.
Ou YH; Torres M; Ram R; Formstecher E; Roland C; Cheng T; Brekken R; Wurz R; Tasker A; Polverino T; Tan SL; White MA
Mol Cell; 2011 Feb; 41(4):458-70. PubMed ID: 21329883
[TBL] [Abstract][Full Text] [Related]
20. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
